SCHEMBL6824744

SCHEMBL6824744

Cc1ccc(-c2[nH]c3ccc(Cl)cc3c2C2=NCCN2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 7/20 0.45
LMNA P02545 3/20 0.43
HTR2A P28223 3/20 0.40
HTR2C P28335 3/20 0.40
HTR2B P41595 1/20 0.40
RECQL P46063 1/20 0.38
MAPT P10636 1/20 0.37
HTR1B P28222 1/20 0.37
HTR7 P34969 1/20 0.37
HTR3A P46098 1/20 0.37
HTR6 P50406 1/20 0.37
MAP3K14 Q99558 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824110 0.91 NISCH (0.48) NISCHLMNAHTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL7738748 0.90 NISCH (0.47) NISCHLMNAHTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL7735530 0.88 NISCH (0.44) NISCHLMNAHTR2AHTR2CHTR2B
SCHEMBL6821391 0.87 NISCH (0.53) NISCHLMNARECQL
SCHEMBL6824677 0.86 NISCH (0.51) NISCHLMNAHTR2AHTR2CHTR2B
SCHEMBL6825016 0.85 NISCH (0.51) NISCHLMNARECQL
Hydrochloric Acid SCHEMBL7736320 0.84 NISCH (0.50) NISCHLMNAHTR2AHTR2CRECQL
SCHEMBL6824458 0.82 NISCH (0.56) NISCHLMNAHTR2AHTR2CRECQL
SCHEMBL6825117 0.82 ATP4A (0.39) NISCHLMNAHTR2AHTR2CRECQL
SCHEMBL6826682 0.81 PTGS2 (0.48) NISCHLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885LMNA 3624/4885HTR2A 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.